StudyRareStudyRare

Ketone body metabolism

Log in to star
Fat and ketone metabolism

Last updated Nov 4, 2026

Log in to add personal notes on this page.

Ketone bodies (acetoacetate and 3-hydroxybutyrate) are the backup fuel for fasting. The liver makes them from the acetyl-CoA of fat oxidation, and the brain, heart, and kidney burn them when glucose runs short. A defect sits on one side or the other, and the two sides look opposite at the bedside: a child who cannot make ketones is hypoglycemic with few or no ketones in the urine, while a child who cannot use them has severe ketoacidosis.

carnitine shuttle, thenbeta-oxidation, in livermitochondriaHMG-CoA synthaseHMGCS2HMG-CoA lyaseHMGCL; releases acetyl-CoA;liver mitochondriaHMG-CoA lyase deficiencymonocarboxylate transporter 1(MCT1)SLC16A1; carries them across theblood-brain barriersuccinyl-CoA:3-oxoacid CoAtransferase, SCOTOXCT1; with succinyl-CoA; thefirst, rate-limiting step ofketone useSCOT deficiencybeta-ketothiolase (T2)ACAT1; also cleaves2-methylacetoacetyl-CoA inisoleucine breakdownbeta-ketothiolase deficiencylong-chain fatacetyl-CoAHMG-CoAacetoacetate,3-hydroxybutyrateacetoacetate inother tissuesacetoacetyl-CoAKrebs cycle
Figure: ketone bodies made in the liver and burned outside it, with HMG-CoA lyase, SCOT, and beta-ketothiolase deficiency at the steps they block.
  1. Fat to acetyl-CoA in the liver: long-chain fat enters mitochondria on the carnitine shuttle and is cut to acetyl-CoA by beta-oxidation.
  2. acetyl-CoA → HMG-CoA: HMG-CoA synthase (HMGCS2).
  3. HMG-CoA → acetoacetate + acetyl-CoA: HMG-CoA lyase (HMGCL), liver mitochondria. This is the shared last step of ketogenesis and of leucine breakdown. Blocked in HMG-CoA lyase deficiency.
  4. Acetoacetate and 3-hydroxybutyrate travel in blood to tissues outside the liver. Monocarboxylate transporter 1 (MCT1, SLC16A1) carries them across the blood-brain barrier into the brain.
  5. acetoacetate + succinyl-CoA → acetoacetyl-CoA: succinyl-CoA:3-oxoacid CoA transferase, SCOT (OXCT1), outside the liver. The first, rate-limiting step of ketone use. Blocked in SCOT deficiency.
  6. acetoacetyl-CoA is cleaved and enters the Krebs cycle: mitochondrial acetoacetyl-CoA thiolase, beta-ketothiolase or T2 (ACAT1). The same enzyme cleaves 2-methylacetoacetyl-CoA in isoleucine breakdown. Blocked in beta-ketothiolase deficiency.
  • HMG-CoA lyase deficiency (cannot make ketones): fasting or illness brings hypoglycemia and metabolic acidosis with no ketosis, often with hyperammonemia and a raised transaminase, so it resembles a fatty acid oxidation defect. Leucine intermediates back up: urine 3-hydroxy-3-methylglutaric, 3-methylglutaconic, and 3-hydroxyisovaleric acids, blood C5-OH and C6DC. Most present in the first year, many as newborns.
  • SCOT deficiency (cannot use ketones): ketones are made normally but cannot be burned, so they accumulate as severe ketoacidotic crises, while the acylcarnitine profile is unremarkable. Ketosis that persists even when the child is well and fed is characteristic, but it can be absent when some SCOT activity remains.
  • Beta-ketothiolase deficiency (cannot use ketones, and an isoleucine block): episodic ketoacidosis, usually starting in the first two years (median 12 months) and rarely as a newborn, with isoleucine metabolites in urine organic acids and C5:1 and C5-OH acylcarnitines. Those acylcarnitines can be normal even during a crisis, so a normal newborn screen does not exclude it.
  • Also on this pathway, without a page here yet: HMG-CoA synthase deficiency (HMGCS2), at step 2, and monocarboxylate transporter 1 deficiency (SLC16A1), a defect of ketone body transport.
  • Ketones during hypoglycemia split the page in two. Absent or low ketones point to HMG-CoA lyase deficiency (or a fat oxidation defect upstream); massive ketones point to SCOT or beta-ketothiolase deficiency, because the liver is making ketones that nothing can burn.
  • Urine organic acids then separate the three: leucine metabolites for HMG-CoA lyase, isoleucine metabolites for beta-ketothiolase, and no specific metabolite for SCOT, which is why SCOT deficiency rests on the clinical pattern and enzyme or OXCT1 testing.
  • The acylcarnitine profile separates HMG-CoA lyase deficiency (C5-OH, C6DC) from a fatty acid oxidation defect, which shares the hypoketotic hypoglycemia.